Literature DB >> 22430611

[NK/T-cell lymphoma, nasal type with cutaneous dissemination].

A M Baran1, J Reifenberger, D Helbig.   

Abstract

Extranodal NK/T-cell lymphoma, nasal type, is a lymphoproliferative disorder originating from peripheral T-cells or natural killer (NK) cells. While it is a rare disease in Europe, it is more frequent in Asia and South America. It is associated with Epstein-Barr virus (EBV) infection and characterized by an extremely aggressive course and poor prognosis. We report a 46-year-old Caucasian woman who presented with multiple subcutaneous, painful nodules on the trunk first noticed a few weeks earlier. In addition to dermatological findings, the patient reported a 4-months history of necrotizing nasopharyngeal inflammation of unclear origin. Due to nonspecific histological and clinical findings mimicking a chronic inflammatory condition, a diagnosis of Wegener disease was made and immunosuppressive therapy with azathioprine was initiated. However the disease progressed under therapy. Histopathological reevaluation and immunophenotyping revealed a disseminated NK/T-cell lymphoma, nasal type. In the case of an unspecific chronic inflammatory process in the nasopharyngeal space one should always consider the possibility of this rare lymphoma, even in Europe.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22430611     DOI: 10.1007/s00105-012-2356-5

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  7 in total

1.  Current management of nasal NK/T-cell lymphoma.

Authors:  Wing Y Au
Journal:  Oncology (Williston Park)       Date:  2010-04-15       Impact factor: 2.990

Review 2.  WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects.

Authors:  Günter Burg; Werner Kempf; Antonio Cozzio; Josef Feit; Rein Willemze; Elaine S Jaffe; Reinhard Dummer; Emilio Berti; Lorenzo Cerroni; Sergio Chimenti; José L Diaz-Perez; Florent Grange; Nancy L Harris; Dmitry V Kazakov; Helmut Kerl; Michael Kurrer; Robert Knobler; Chris J L M Meijer; Nicola Pimpinelli; Elisabeth Ralfkiaer; Robin Russell-Jones; Christian Sander; Marco Santucci; Wolfram Sterry; Steven H Swerdlow; Maarten H Vermeer; Janine Wechsler; Sean Whittaker
Journal:  J Cutan Pathol       Date:  2005-11       Impact factor: 1.587

Review 3.  Extranodal natural killer/T-cell lymphoma: advances in the management.

Authors:  Arnaud Jaccard; Olivier Hermine
Journal:  Curr Opin Oncol       Date:  2011-09       Impact factor: 3.645

Review 4.  [Clinico-pathologic forms of peripheral T-and NK-cell lymphomas].

Authors:  H D Foss; S E Coupland; H Stein
Journal:  Pathologe       Date:  2000-03       Impact factor: 1.011

Review 5.  [Primary nasal natural killer/T-cell lymphomas: classification and clinicopathological features].

Authors:  A Sandner; S Kösling; P Helmbold; M Winkler; M B Bloching; H-J Holzhausen
Journal:  HNO       Date:  2007-02       Impact factor: 1.284

6.  Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.

Authors:  Motoko Yamaguchi; Yok-Lam Kwong; Won Seog Kim; Yoshinobu Maeda; Chizuko Hashimoto; Cheolwon Suh; Koji Izutsu; Fumihiro Ishida; Yasushi Isobe; Eisaburo Sueoka; Junji Suzumiya; Takao Kodama; Hiroshi Kimura; Rie Hyo; Shigeo Nakamura; Kazuo Oshimi; Ritsuro Suzuki
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

7.  Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology.

Authors:  E S Jaffe; J K Chan; I J Su; G Frizzera; S Mori; A C Feller; F C Ho
Journal:  Am J Surg Pathol       Date:  1996-01       Impact factor: 6.394

  7 in total
  1 in total

1.  Treatment outcome of radiotherapy alone versus radiochemotherapy in IE/IIE extranodal nasal-type natural killer/T cell lymphoma: a meta-analysis.

Authors:  Tianxia Deng; Cheng Zhang; Xi Zhang; Sha Wu; Yaqi Xu; Shanshan Liu; Xinghua Chen
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.